Celgene Corporation 7 Powder Horn Drive Warren, New Jersey 07059License Agreement • March 16th, 2005 • Pharmion Corp • Pharmaceutical preparations
Reference is made to that certain License Agreement, dated as of November 16, 2001, as amended by Amendment No. 1, dated March 3, 2003, as further amended by Amendment No. 2, dated April 8, 2003, and as further amended by that letter agreement, dated August 18, 2003, by and among Pharmion GmbH, Pharmion Corporation (“Pharmion”) and Celgene Corporation (“Celgene”) (the “License Agreement”). Except as otherwise indicated, capitalized terms used herein have the meaning ascribed to them in the License Agreement.
Dated 21 December 2004Lease Agreement • March 16th, 2005 • Pharmion Corp • Pharmaceutical preparations
Pharmion Corporation 2525 28th Street Boulder, Colorado 80301License Agreement • March 16th, 2005 • Pharmion Corp • Pharmaceutical preparations • New York
Pharmion GmbH (“Pharmion”), Pharmion Corporation (“Guarantor”) and Celgene Corporation (“Celgene”) have previously entered into a License Agreement dated November 16, 2001, as subsequently amended (the “License Agreement”) pursuant to which Celgene has granted to Pharmion a license for Thalidomide products, including its Thalomid formulation. To further their mutual interests in Pharmion obtaining regulatory approval for the marketing and sale of Thalomid in the Territory (as defined in the License Agreement), Pharmion, Guarantor and Celgene have previously established a working relationship relating to the clinical development of Thalomid under a letter agreement dated April 2, 2003 (“2003 Clinical Trials Agreement”). Subsequently, on the basis of advice from the European Agency for the Evaluation of Medicinal Products (“EMEA”) that it would require additional clinical data for Thalomid before it could reach an opinion on whether or not the drug should be approved as a treatment for m
GUARANTEE of a Lease of Riverside House, Riverside Walk, Windsor SL4 1NAGuarantee of a Lease • March 16th, 2005 • Pharmion Corp • Pharmaceutical preparations
WHEREAS this Deed is entered into by the Guarantor in consideration of the Landlord at the request of the Guarantor agreeing to grant the Lease to the Tenant.
Amendment No. 2 to Amended and Restated Distribution and License AgreementDistribution Agreement • March 16th, 2005 • Pharmion Corp • Pharmaceutical preparations • England and Wales
This Amendment No. 2, dated December 3, 2004, to the Amended and Restated Distribution and License Agreement, dated as of November 16, 2001 (the “Supply Agreement”), by and between Pharmion GmbH, a Swiss limited liability company (“Pharmion”), and Celgene UK Manufacturing II Limited (formerly, Penn T Limited), a corporation organized under the laws of England and Wales (“CUK”), as amended by Amendment No. 1 to the Amended and Restated Distribution and License Agreement, dated March 4, 2003, by and between Pharmion and CUK (“Amendment No. 1”), and as supplemented by the Supplementary Agreement to the Amended and Restated Distribution and License Agreement, dated June 18, 2003, by and between Pharmion and CUK (the “Supplementary Agreement”).
